Breaking News
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - High diet quality associated with lower risk of death in colorectal cancer patients
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - Research provides insight into neurobiology of aggression and bullying
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
October 21, 2018 - Increased cardiorespiratory fitness associated with reduced long-term mortality
October 21, 2018 - IU researchers receive $1.55 million from NIH to improve chronic-disease management
October 21, 2018 - Income and wealth affect the mental health of Australians, study shows
October 21, 2018 - Patients with hypertension and psoriasis more often require cardiovascular interventions
October 20, 2018 - Leading hip-hop videos depict use of tobacco and marijuana products, study finds
October 20, 2018 - Dose Range of IV Ketamine for Adjunct Tx of Depression Tested
October 20, 2018 - Infants can distinguish between leaders and bullies, study finds
October 20, 2018 - Mad Cow disease found on Aberdeenshire farm
October 20, 2018 - Study identifies factors associated with prescription opioid misuse among students
October 20, 2018 - Scientists uncover key regulator of mTORC1 in cancer growth
October 20, 2018 - Pounds Regained After Weight-Loss Op Can Tell Your Doc a Lot
October 20, 2018 - Sending parents letters to fight childhood obesity doesn’t work
October 20, 2018 - Supervised aerobic exercise can support major depression treatment
October 20, 2018 - Mindfulness-based program effective for reducing stress in infertile women
October 20, 2018 - Molecule capable of halting and reverting neurodegeneration caused by Parkinson’s disease identified
October 20, 2018 - Midazolam-mediated alterations of PER2 expression may have functional consequences during myocardial ischemia
October 20, 2018 - Sweat bees are ideal for studying the genes underlying social behavior
October 20, 2018 - Weight loss success associated with brain areas involved in self-control
October 20, 2018 - KHN’s ‘What the Health?’ Republicans’ preexisting political problem
October 20, 2018 - Research provides a more complete picture of suffering caused by terrorist attacks
October 20, 2018 - Eradicating Helicobacter pylori infections may be a key treatment for Parkinson’s disease
October 20, 2018 - Breast Cancer as a Dynamic Disease
October 20, 2018 - University of Pittsburgh wins NSF grant for big data research to prevent complications from anesthesia
October 20, 2018 - Skin-to-skin contact may promote attachment between parents and preterm infants
October 20, 2018 - Recommendations Developed to Verify NGT Placement in Children
Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s

Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s

image_pdfDownload PDFimage_print

Action Points

  • Upfront treatment with the antibody-drug conjugate brentuximab vedotin (Adcetris) led to significantly better progression-free survival for patients with newly diagnosed advanced Hodgkin lymphoma.
  • The addition of brentuximab to chemotherapy increased rates of neutropenia and peripheral neuropathy, which was manageable in most cases.

ATLANTA — Upfront treatment with the antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) led to significantly better progression-free survival (PFS) for patients with newly diagnosed advanced Hodgkin lymphoma, investigators reported here.

Patients who received the ADC, in addition to standard first-line chemotherapy, had a 2-year PFS of 82.1% versus 77.2% for chemotherapy alone. An interim analysis of overall survival (OS) showed a trend in favor of the brentuximab regimen, but the difference did not achieve statistical significance, according to James M. Connors, MD, of the British Columbia Cancer Agency in Vancouver, and colleagues.

The addition of brentuximab to chemotherapy increased rates of neutropenia and peripheral neuropathy, which was manageable in most cases, Connors said during a presentation at the American Society of Hematology meeting. The study was published simultaneously in the New England Journal of Medicine.

The trial also provided support for omitting bleomycin from chemotherapy when brentuximab is used.

“The (brentuximab) regimen is associated with more myelotoxicity — which can be ameliorated with prophylactic G-CSF — and neurotoxicity — which is largely reversible) than ABVD but substantially less pulmonary toxicity and appears to be more effective for the frontline treatment of advanced-stage classic Hodgkin’s lymphoma,” Connors’ group wrote.

Authors of an accompanying NEJM editorial cautioned that follow-up time for the study was too brief to rule out the possibility of late side effects with brentuximab regimen. However, they gave tentative support for upfront use of the ADC.

“It appears that the addition of brentuximab vedotin to AVD combination chemotherapy … merits consideration as first-line treatment for advanced Hodgkin’s lymphoma,” wrote Daniel Longo, MD, and Vincent T. DeVita Jr., MD, both of Yale Cancer Center in New Haven, Connecticut. “Although the follow-up time has been relatively short the (ADC combination) appears to be more effective than ABVD (and is unlikely to be less effective) and is associated with fewer, more treatable toxicities.”

Outcomes for advanced Hodgkin’s lymphoma improved substantially over the past 50 years, especially after the introduction of ABVD combination chemotherapy (doxorubicin-bleomycin-vinblastine-dacarbazine) more than 40 years ago. However, 25% to 30% of patients have refractory disease or relapse after initial treatment with ABVD, Connors’ group noted. Moreover, bleomycin can cause unpredictable and potentially fatal pulmonary toxicity.

Brentuximab vedotin consists of a monoclonal antibody that targets the CD30 surface antigen — expressed by Reed-Sternberg cells in classic Hodgkin’s lymphoma — to the microtubule-disrupting agent monomethyl auristatin. The ADC has FDA approval as treatment for classic Hodgkin’s lymphoma that does not respond, or recurs after stem-cell transplantation or failure of at least two multiagent chemotherapy regimens. The drug also has approval as posttransplant consolidation therapy for high-risk patients.

The decision to include bleomycin in chemotherapy (ABVD) remains controversial, both in terms of efficacy and added toxicity, particularly pulmonary toxicity. In a phase I trial of frontline therapy for advanced Hodgkin’s lymphoma, brentuximab vedotin combined with AVD chemotherapy led to complete responses in 24 of 25 patients, a 5-year failure-free survival of 92%, and OS of 100%.

Connors presented results from a phase III randomized trials to compare brentuximab vedotin plus AVD chemotherapy with standard ABVD chemotherapy in 1,334 patients with untreated stage III or IV classic Hodgkin’s lymphoma. The trial had a primary endpoint of modified PFS — the time to disease progression, death, or non-complete response and use of subsequent anticancer therapy, adjudicated by an independent review committee.

The study population had a median age of 36, and men accounted for 58% of the patients. Two-thirds of the patients had stage IV disease, 62% had extranodal involvement at diagnosis, and 58% had B symptoms (such as night sweats, weight loss, and fever).

After a median follow-up of 25 months, the brentuximab regimen had resulted in a 23% reduction in the hazard for the primary endpoint (95% CI 0.60-0.98, P=0.03). The preliminary survival analysis showed that 28 patients ion the brentuximab arm died versus 39 in the ABVD arm, which translated into a nonsignificant 28% reduction in the hazard ratio in favor of brentuximab (95% CI 0.44-1.17, P=0.19).

With respect to safety, the most common adverse event in both groups was neutropenia, which occurred in 58% of the brentuximab arm and 45% of the ABVD arm. Febrile neutropenia occurred in 19% and 8% of the brentuximab and ABVD groups, respectively. In the brentuximab arm, febrile neutropenia occurred less in of 83 patients who received prophylactic G-CSF (11% vs 21%). Connors said 1% of patients in each group discontinued because of febrile neutropenia.

Other common adverse events (any grade) were infection (55% vs 50%), constipation (42% with brentuximab, 37% with ABVD), vomiting (33% vs 28%), fatigue (32% in both groups), peripheral sensory neuropathy (29% vs 17%), diarrhea (27% vs 18%), pyrexia (26% vs 13%), abdominal pain (21% vs 10%), and stomatitis (21% vs 16%). Neutropenia (54% vs 39%) was the only grade 3 adverse event that occurred in more than 5% of patients in either group.

Pulmonary toxicity occurred in 2% and 7% of the brentuximab and ABVD groups, respectively, including grade ≥3 pulmonary toxicity in 1% and 3%.

The study was supported by Seattle Genetics and Millennium Pharmaceuticals.

Connors disclosed relevant relationships with Janssen, Genentech, NanoString Technologies, Merck, F Hoffmann-La Roche, Cephalon, Seattle Genetics, Bayer Healthcare, Bristol-Myers Squibb, Takeda, Amgen, and Eli Lilly.

Longo disclosed serving as deputy editor of the New England Journal of Medicine. DeVita disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-12T00:00:00-0500

last updated

Tagged with:

About author

Related Articles